Failure of estrogen plus progestin therapy for prevention

Journal of the American Medical Association

Volumn 288, Issue 3, 2002, Pages 366-368

  Fletcher, Suzanne W ^a,b   Colditz, Graham A ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD PILGRIM HEALTH CARE   (United States)

^c CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN;

BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL CANCER; EDITORIAL; ESTROGEN THERAPY; FEMALE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; METHODOLOGY; OSTEOPOROSIS; POSTMENOPAUSE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STROKE; TREATMENT FAILURE;

EID: 0037125455     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.3.366     Document Type: Editorial

References (20)

1. Use of hormone replacement therapy by postmenopausal women in the United States
2. Use of postmenopausal estrogens and medroxyprogesterone in the United States, 1982-1992
3. The risk of breast cancer after estrogen and estrogen-progestin replacement
4. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
5. Effect of hormone replacement therapy on breast cancer: Estrogen versus estrogen plus progestin
6. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
7. Risks of breast and endometrial cancer after estrogen and progestin replacement
8. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk
9. The protective effects of estrogen on the cardiovascular system
10. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
11. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up
12. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study: A prospective observational study
13. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
14. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)
15. Hormone replacement therapy in relation to breast cancer
16. Treatment of postmenopausal osteoporosis
17. Tamoxifen for prevention of breast cancer- Report of the National Surgical Adjuvant Breast and Bowel Project P-1
18. The effect of raloxifene on risk of breast cancer in postmenopausal women